Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Capecitabine
Drug ID BADD_D00349
Description Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Indications and Usage For the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen. May also be used in combination with docetaxel for the treatment of metastatic breast cancer in patients who have failed to respond to, or recurred or relasped during or following anthracycline-containing chemotherapy. Capecitabine is used alone as an adjuvant therapy following the complete resection of primary tumor in patients with stage III colon cancer when monotherapy with fluroprymidine is preferred. The use or capecitabine in combination regimens for advanced gastric cancer is currently being investigated.
Marketing Status Prescription
ATC Code L01BC06
DrugBank ID DB01101
KEGG ID D01223
MeSH ID D000069287
PubChem ID 60953
TTD Drug ID D00HCQ
NDC Product Code 72205-007; 69097-948; 59923-722; 59651-204; 0378-2511; 55111-893; 55111-496; 0054-0272; 72205-006; 70756-816; 50268-154; 51407-095; 15308-0714; 16714-467; 62756-239; 67877-458; 64980-277; 55512-0015; 16729-072; 68001-487; 67877-459; 55111-497; 51079-510; 35369-0010; 54893-0002; 70756-815; 63482-099; 60687-149; 0004-1101; 62331-043; 72485-205; 53183-4009; 69539-019; 0004-1100; 65162-843; 16729-073; 72969-094; 62756-238; 16714-468; 68554-0033; 69097-949; 54245-7014; 72485-204; 62756-088; 0054-0271; 59651-205; 0093-7473; 72606-555; 76302-001; 69539-020; 65162-844; 53104-7618; 0378-2512; 51407-096; 81955-0001; 63759-0001; 49452-1713; 68001-488; 65129-1241; 64980-276; 0093-7474; 72606-554; 59923-721
Synonyms Capecitabine | N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine | Xeloda
Chemical Information
Molecular Formula C15H22FN3O6
CAS Registry Number 154361-50-9
SMILES CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Encephalopathy17.13.02.001--
Enteritis07.08.03.0020.009857%
Enterocolitis07.08.03.0030.006394%
Enterocolitis haemorrhagic07.08.01.007; 24.07.02.0060.000799%Not Available
Eosinophilia01.02.04.001--
Epilepsy17.12.03.002--Not Available
Epistaxis24.07.01.005; 22.04.03.001--
Erysipelas23.09.01.002; 11.02.06.0010.000799%Not Available
Erythema23.03.06.0010.029305%Not Available
Erythema multiforme23.03.01.003; 10.01.03.015--
Erythema nodosum23.07.02.001; 10.02.01.0200.000533%Not Available
Exostosis15.02.04.005--
Extrapyramidal disorder17.01.02.007--
Extrasystoles02.03.02.003--Not Available
Eye discharge06.04.05.0010.000533%Not Available
Eye disorder06.08.03.001--Not Available
Eye irritation06.04.05.0030.003197%Not Available
Eye pain06.08.03.002--
Eye swelling06.08.03.003--Not Available
Eyelid oedema23.04.01.003; 10.01.05.001; 06.04.04.004--Not Available
Eyelid ptosis17.17.02.004; 06.05.01.0020.001066%Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Facial bones fracture15.08.04.001; 12.04.05.0020.000533%Not Available
Facial pain08.01.08.012--
Facial paralysis17.04.03.0080.001598%Not Available
Faeces discoloured07.01.03.002--Not Available
Failure to thrive19.07.05.001; 14.03.02.008; 18.04.01.003--Not Available
Fatigue08.01.01.0020.060209%
Febrile neutropenia08.05.02.004; 01.02.03.0020.023178%
Feeling abnormal08.01.09.014--Not Available
The 8th Page    First    Pre   8 9 10 11 12    Next   Last    Total 35 Pages